Susan B Bressler1, Adam R Glassman2, Talat Almukhtar3, Neil M Bressler1, Frederick L Ferris4, Joseph M Googe5, Shailesh K Gupta6, Lee M Jampol7, Michele Melia3, John A Wells8. 1. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Jaeb Center for Health Research, Inc, Tampa, Florida. Electronic address: drcrstat2@jaeb.org. 3. Jaeb Center for Health Research, Inc, Tampa, Florida. 4. National Eye Institute, Bethesda, Maryland. 5. Southeastern Retina Associates, PC, Knoxville, Tennessee. 6. Department of Ophthalmology, University of Florida College of Medicine, Jacksonville, Florida. 7. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 8. Palmetto Retina Center, Columbia, South Carolina.
Abstract
PURPOSE: To compare long-term vision and anatomic effects of ranibizumab with prompt or deferred laser vs laser or triamcinolone + laser with very deferred ranibizumab in diabetic macular edema (DME). DESIGN: Randomized clinical trial. METHODS:Eight hundred and twenty-eight study eyes (558 [67%] completed the 5-year visit), at 52 sites, with visual acuity 20/32 to 20/320 and DME involving the central macula were randomly assigned to intravitreous ranibizumab (0.5 mg) with either (1) prompt or (2) deferred laser; (3) sham injection + prompt laser; or (4) intravitreous triamcinolone (4 mg) + prompt laser. The latter 2 groups could initiate ranibizumab as early as 74 weeks from baseline, for persistent DME with vision impairment. The main outcome measures were visual acuity, optical coherence central subfield thickness, and number of injections through 5 years. RESULTS: At 5 years mean (± standard deviation) change in Early Treatment Diabetic Retinopathy Study visual acuity letter scores from baseline in the ranibizumab + deferred laser (N = 111), ranibizumab + prompt laser (N = 124), laser/very deferred ranibizumab (N = 198), and triamcinolone + laser/very deferred ranibizumab (N = 125) groups were 10 ± 13, 8 ± 13, 5 ± 14, and 7 ± 14, respectively. The difference (95% confidence interval) in mean change between ranibizumab + deferred laser and laser/very deferred ranibizumab and triamcinolone + laser/very deferred ranibizumab was 4.4 (1.2-7.6, P = .001) and 2.8 (-0.9 to 6.5, P = .067), respectively, at 5 years. CONCLUSIONS: Recognizing limitations of follow-up available at 5 years, eyes receiving initial ranibizumab therapy for center-involving DME likely have better long-term vision improvements than eyes managed with laser or triamcinolone + laser followed by very deferred ranibizumab for persistent thickening and vision impairment.
RCT Entities:
PURPOSE: To compare long-term vision and anatomic effects of ranibizumab with prompt or deferred laser vs laser or triamcinolone + laser with very deferred ranibizumab in diabetic macular edema (DME). DESIGN: Randomized clinical trial. METHODS: Eight hundred and twenty-eight study eyes (558 [67%] completed the 5-year visit), at 52 sites, with visual acuity 20/32 to 20/320 and DME involving the central macula were randomly assigned to intravitreous ranibizumab (0.5 mg) with either (1) prompt or (2) deferred laser; (3) sham injection + prompt laser; or (4) intravitreous triamcinolone (4 mg) + prompt laser. The latter 2 groups could initiate ranibizumab as early as 74 weeks from baseline, for persistent DME with vision impairment. The main outcome measures were visual acuity, optical coherence central subfield thickness, and number of injections through 5 years. RESULTS: At 5 years mean (± standard deviation) change in Early Treatment Diabetic Retinopathy Study visual acuity letter scores from baseline in the ranibizumab + deferred laser (N = 111), ranibizumab + prompt laser (N = 124), laser/very deferred ranibizumab (N = 198), and triamcinolone + laser/very deferred ranibizumab (N = 125) groups were 10 ± 13, 8 ± 13, 5 ± 14, and 7 ± 14, respectively. The difference (95% confidence interval) in mean change between ranibizumab + deferred laser and laser/very deferred ranibizumab and triamcinolone + laser/very deferred ranibizumab was 4.4 (1.2-7.6, P = .001) and 2.8 (-0.9 to 6.5, P = .067), respectively, at 5 years. CONCLUSIONS: Recognizing limitations of follow-up available at 5 years, eyes receiving initial ranibizumab therapy for center-involving DME likely have better long-term vision improvements than eyes managed with laser or triamcinolone + laser followed by very deferred ranibizumab for persistent thickening and vision impairment.
Authors: Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun Journal: Ophthalmology Date: 2010-04-28 Impact factor: 12.079
Authors: Michael J Elman; Allison Ayala; Neil M Bressler; David Browning; Christina J Flaxel; Adam R Glassman; Lee M Jampol; Thomas W Stone Journal: Ophthalmology Date: 2014-10-28 Impact factor: 12.079
Authors: Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun Journal: Ophthalmology Date: 2011-04 Impact factor: 12.079
Authors: David M Brown; Quan Dong Nguyen; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Patricio G Schlottmann; Amy Chen Rundle; Jiameng Zhang; Roman G Rubio; Anthony P Adamis; Jason S Ehrlich; J Jill Hopkins Journal: Ophthalmology Date: 2013-05-22 Impact factor: 12.079
Authors: Ursula Schmidt-Erfurth; Gabriele E Lang; Frank G Holz; Reinier O Schlingemann; Paolo Lanzetta; Pascale Massin; Ortrud Gerstner; Abdelkader Si Bouazza; Haige Shen; Aaron Osborne; Paul Mitchell Journal: Ophthalmology Date: 2014-02-01 Impact factor: 12.079
Authors: Susan B Bressler; Danni Liu; Adam R Glassman; Barbara A Blodi; Alessandro A Castellarin; Lee M Jampol; Paul L Kaufman; Michele Melia; Harinderjit Singh; John A Wells Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Eric J Kim; Weijie V Lin; Sean M Rodriguez; Ariel Chen; Asad Loya; Christina Y Weng Journal: Curr Diab Rep Date: 2019-07-29 Impact factor: 4.810
Authors: Philipp K Roberts; Wolf-Dieter Vogl; Bianca S Gerendas; Adam R Glassman; Hrvoje Bogunovic; Lee M Jampol; Ursula M Schmidt-Erfurth Journal: JAMA Ophthalmol Date: 2020-09-01 Impact factor: 7.389